Immunova to Acquire AlphaTON Subsidiary Iox Therapeutics
Immunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
Knowing when to change your investment strategy is crucial. Discover key signs that indicate it's time to adapt.
24,241 articlesImmunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
As 2026 opens with mixed signals, investors seek ballast. This story examines three dividend ETFs that actually shiel...
A new market for tariff refunds is taking shape as courts clarify refund rights, drawing funds and individuals into a...
Bitcoin’s mining difficulty jumped about 15% to roughly 144T, signaling a rapid shift in miner economics. Early on-ch...
Aave Labs unveiled a multi-layered security framework for its V4 release, backed by a $1.5 million audit program. The...
Analysts kicked off the week with a wave of fresh calls on major names, signaling a mixed tone across consumer, tech ...
PennyMac’s Third-Party Origination unit rolls out a seven-program non-QM suite to broaden options for borrowers with ...
In Washington, governors from both parties pressed for a sweeping review of the nation’s workforce policy amid AI-dri...
Oracle has big cloud plans, aiming for massive revenue growth by 2030. A pivotal $110 billion catalyst could make tha...
A sharp look at how perfectly rational branding decisions can erode meaning. Intel and Toyota illustrate why investor...
Insmed disclosed that Japan now hosts more MAC lung disease patients than the United States, a development that could...
Beyond Meat faces a double headwind: a tepid forecast and a crowded protein-drink market. Investors are reeling as re...